9. NTL4: The Next Generation Topical Anesthetic Optimized 4% Topical Lidocaine in a Unique Nano Technology Delivery System Results of Clinical Trials Comparing NTL4 to LMX4 Protocols N ° 10025 10025.1 Center for Clinical and Cosmetic Research (CCCR), Aventura, Florida Mark S. Nestor, M.D., Ph.D.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24. Efficacy Results: Subjective VAS Early Onset (5 Minutes) (N=6) N=6 N=6 N=6 p=0.045 p=0.309 p=0.643 d=0.61 (Large) d=0.27 (Small) X Axis: Time After Injection Y Axis: VAS Scale
25. Subjective Level of Pain Early Onset (5 Minutes) (N=6) P=0.079 LMX4 NTL4 Product_Randomization 4 3 2 1 0 Count Moderate Pain Mild Pain Minimal Pain No Pain Subject_Level_of_Pain Bar Chart
27. Blinded Investigator’s Evaluation of Pain Early Onset (5 Minutes) (N=6) P=0.076 LMX4 NTL4 Product_Randomization 4 3 2 1 0 Count Mild Pain Minimal Pain No Pain Subject_Level_of_Pain Bar Chart
28. VAS Comparison: Onset Immediate Post Injection N=30 N=6 N=8 N=6 p=0.044 p=0.004 p=0.068 p=0.045 d=0.98 (Large) X Axis: Duration of Application Y Axis: VAS Scale